NCT02170337View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
DRUG

AMG 282

AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps

DRUG

Placebo

Contains no active drug

Trial Locations (4)

33143

Research Site, South Miami

77030

Research Site, Houston

80045

Research Site, Aurora

90404

Research Site, Santa Monica

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02170337 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps | Biotech Hunter | Biotech Hunter